Green Valley Investors LLC Sells 7,271 Shares of Vertex Pharmaceuticals Incorporated (VRTX)
Green Valley Investors LLC lowered its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 3.8% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 185,430 shares of the pharmaceutical company’s stock after selling 7,271 shares during the period. Vertex Pharmaceuticals comprises 1.2% of Green Valley Investors LLC’s holdings, making the stock its 25th biggest holding. Green Valley Investors LLC owned about 0.07% of Vertex Pharmaceuticals worth $23,896,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also made changes to their positions in VRTX. Russell Investments Group Ltd. grew its stake in shares of Vertex Pharmaceuticals by 32.1% in the 1st quarter. Russell Investments Group Ltd. now owns 96,922 shares of the pharmaceutical company’s stock worth $10,600,000 after purchasing an additional 23,528 shares during the last quarter. US Bancorp DE grew its stake in shares of Vertex Pharmaceuticals by 104.9% in the 1st quarter. US Bancorp DE now owns 7,324 shares of the pharmaceutical company’s stock worth $801,000 after purchasing an additional 3,749 shares during the last quarter. RNC Capital Management LLC acquired a new position in shares of Vertex Pharmaceuticals in the 1st quarter worth approximately $309,000. Karp Capital Management Corp acquired a new position in shares of Vertex Pharmaceuticals in the 1st quarter worth approximately $7,514,000. Finally, Sei Investments Co. grew its stake in shares of Vertex Pharmaceuticals by 2.8% in the 1st quarter. Sei Investments Co. now owns 66,016 shares of the pharmaceutical company’s stock worth $7,218,000 after purchasing an additional 1,817 shares during the last quarter. 92.88% of the stock is currently owned by institutional investors.
Shares of Vertex Pharmaceuticals Incorporated (VRTX) traded down 0.52% during mid-day trading on Monday, hitting $158.00. 397,700 shares of the stock were exchanged. The company has a market capitalization of $39.83 billion, a PE ratio of 151.78 and a beta of 1.75. Vertex Pharmaceuticals Incorporated has a 12-month low of $71.46 and a 12-month high of $167.85. The firm has a 50-day moving average price of $155.29 and a 200 day moving average price of $125.22.
Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.39 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.33. Vertex Pharmaceuticals had a net margin of 12.05% and a return on equity of 4.64%. The business had revenue of $544.10 million during the quarter, compared to analysts’ expectations of $489.95 million. During the same period last year, the business earned $0.24 earnings per share. The firm’s revenue was up 26.1% on a year-over-year basis. On average, equities research analysts expect that Vertex Pharmaceuticals Incorporated will post $1.60 earnings per share for the current year.
Several research firms have recently weighed in on VRTX. J P Morgan Chase & Co set a $184.00 target price on shares of Vertex Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, July 27th. Oppenheimer Holdings, Inc. lifted their target price on shares of Vertex Pharmaceuticals from $150.00 to $175.00 and gave the stock an “outperform” rating in a research report on Thursday, July 27th. Maxim Group set a $195.00 target price on shares of Vertex Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, July 27th. Morgan Stanley reissued an “overweight” rating and issued a $190.00 target price (up from $153.00) on shares of Vertex Pharmaceuticals in a research report on Saturday, July 22nd. Finally, Vetr downgraded shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $181.00 target price on the stock. in a research report on Monday, July 24th. Six research analysts have rated the stock with a hold rating and twenty-two have issued a buy rating to the stock. Vertex Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $162.88.
ILLEGAL ACTIVITY NOTICE: “Green Valley Investors LLC Sells 7,271 Shares of Vertex Pharmaceuticals Incorporated (VRTX)” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another site, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/09/11/green-valley-investors-llc-sells-7271-shares-of-vertex-pharmaceuticals-incorporated-vrtx.html.
In related news, SVP Paul M. Silva sold 43,443 shares of the firm’s stock in a transaction on Friday, July 21st. The shares were sold at an average price of $161.07, for a total value of $6,997,364.01. Following the completion of the transaction, the senior vice president now directly owns 26,516 shares of the company’s stock, valued at $4,270,932.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CMO Jeffrey Chodakewitz sold 573 shares of the firm’s stock in a transaction on Monday, July 17th. The shares were sold at an average price of $129.85, for a total transaction of $74,404.05. Following the completion of the transaction, the chief marketing officer now directly owns 123,084 shares of the company’s stock, valued at $15,982,457.40. The disclosure for this sale can be found here. Insiders sold 526,092 shares of company stock valued at $84,101,702 over the last three months. 1.80% of the stock is owned by company insiders.
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.
Receive News & Stock Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related stocks with our FREE daily email newsletter.